In the preceding three months, 12 analysts have released ratings for Agilent Technologies (NYSE:A), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 6 | 2 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 3 | 5 | 2 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Agilent Technologies, revealing an average target of $172.5, a high estimate of $185.00, and a low estimate of $160.00. Marking an increase of 10.34%, the current average surpasses the previous average price target of $156.33.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Agilent Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Sidharth Sahoo | HSBC | Announces | Buy | $180.00 | - |
| Vijay Kumar | Evercore ISI Group | Raises | Outperform | $160.00 | $155.00 |
| Luke Sergott | Barclays | Maintains | Overweight | $165.00 | $165.00 |
| Evie Koslosky | Goldman Sachs | Announces | Buy | $170.00 | - |
| Kallum Titchmarsh | Morgan Stanley | Announces | Overweight | $180.00 | - |
| Patrick Donnelly | Citigroup | Raises | Buy | $185.00 | $165.00 |
| Dan Leonard | UBS | Raises | Buy | $180.00 | $170.00 |
| Brandon Couillard | Wells Fargo | Raises | Overweight | $175.00 | $150.00 |
| Casey Woodring | JP Morgan | Raises | Overweight | $180.00 | $165.00 |
| Luke Sergott | Barclays | Raises | Equal-Weight | $165.00 | $145.00 |
| Catherine Schulte | Baird | Raises | Outperform | $165.00 | $142.00 |
| Derik De Bruin | B of A Securities | Raises | Neutral | $165.00 | $150.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Agilent Technologies. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Agilent Technologies compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Agilent Technologies's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Agilent Technologies's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Agilent Technologies analyst ratings.
About Agilent Technologies
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Key Indicators: Agilent Technologies's Financial Health
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3M period, Agilent Technologies showcased positive performance, achieving a revenue growth rate of 9.41% as of 31 October, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Agilent Technologies's net margin is impressive, surpassing industry averages. With a net margin of 23.32%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Agilent Technologies's ROE excels beyond industry benchmarks, reaching 6.62%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Agilent Technologies's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.48%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.5.
Analyst Ratings: Simplified
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
